PEOPLE

Randy Sweis, MD, is a physician-scientist dedicated to developing the next generation of immunotherapeutic treatments for cancer patients, while training the next generation of cancer immunotherapy researchers. His research program has received numerous accolades, including the AACR Translational Immuno-Oncology Award, the American Society of Clinical Oncology Young Investigator Award, and the Cancer Research Foundation Young Investigator Award. His laboratory has been continuously funded by the National Institutes of Health since its inception. Complementary to his laboratory research, Sweis has clinical expertise in phase I trials for advanced solid tumors with a focus on genitourinary malignancies. He has served as a Principal Investigator on over 30 clinical trials, including TCR-based therapies; intratumoral immunotherapies; checkpoint therapy; cytokine therapy; microbiome-modifying approaches; and viral-, vaccine-, and RNA-based therapies. His overarching goal is the identification and targeting of immunotherapy resistance pathways for rapid translation into clinical trials for patients.